Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Neuronal nicotinic receptor agonists improve gait and balance in olivocerebellar ataxia.

Wecker L, Engberg ME, Philpot RM, Lambert CS, Kang CW, Antilla JC, Bickford PC, Hudson CE, Zesiewicz TA, Rowell PP.

Neuropharmacology. 2013 Oct;73:75-86. doi: 10.1016/j.neuropharm.2013.05.016. Epub 2013 May 24.

2.

Analysis of gait in rats with olivocerebellar lesions and ability of the nicotinic acetylcholine receptor agonist varenicline to attenuate impairments.

Lambert CS, Philpot RM, Engberg ME, Johns BE, Wecker L.

Behav Brain Res. 2015 Sep 15;291:342-50. doi: 10.1016/j.bbr.2015.05.056. Epub 2015 Jun 3.

3.

Varenicline and mecamylamine attenuate locomotor sensitization and cross-sensitization induced by nicotine and morphine in mice.

Biala G, Staniak N.

Pharmacol Biochem Behav. 2010 Aug;96(2):141-7. doi: 10.1016/j.pbb.2010.04.022. Epub 2010 May 6.

PMID:
20451547
4.

Varenicline blocks β2*-nAChR-mediated response and activates β4*-nAChR-mediated responses in mice in vivo.

Ortiz NC, O'Neill HC, Marks MJ, Grady SR.

Nicotine Tob Res. 2012 Jun;14(6):711-9. doi: 10.1093/ntr/ntr284. Epub 2012 Jan 12.

5.

Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of alpha4beta2 nicotinic receptors in rats.

Spiller K, Xi ZX, Li X, Ashby CR Jr, Callahan PM, Tehim A, Gardner EL.

Neuropharmacology. 2009 Jul;57(1):60-6. doi: 10.1016/j.neuropharm.2009.04.006. Epub 2009 Apr 22.

6.

The effects of nicotine, varenicline, and cytisine on schedule-controlled responding in mice: differences in α4β2 nicotinic receptor activation.

Cunningham CS, McMahon LR.

Eur J Pharmacol. 2011 Mar 1;654(1):47-52. doi: 10.1016/j.ejphar.2010.12.003. Epub 2010 Dec 21.

7.

A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3.

Zesiewicz TA, Greenstein PE, Sullivan KL, Wecker L, Miller A, Jahan I, Chen R, Perlman SL.

Neurology. 2012 Feb 21;78(8):545-50. doi: 10.1212/WNL.0b013e318247cc7a. Epub 2012 Feb 8. Erratum in: Neurology. 2012 Jul 31;79(5):488.

PMID:
22323747
8.

The nicotinic acetylcholine receptor partial agonist varenicline increases the ataxic and sedative-hypnotic effects of acute ethanol administration in C57BL/6J mice.

Kamens HM, Andersen J, Picciotto MR.

Alcohol Clin Exp Res. 2010 Dec;34(12):2053-60. doi: 10.1111/j.1530-0277.2010.01301.x. Epub 2010 Oct 14.

9.

Selective α4β2 nicotinic acetylcholine receptor agonists target epigenetic mechanisms in cortical GABAergic neurons.

Maloku E, Kadriu B, Zhubi A, Dong E, Pibiri F, Satta R, Guidotti A.

Neuropsychopharmacology. 2011 Jun;36(7):1366-74. doi: 10.1038/npp.2011.21. Epub 2011 Mar 2.

10.

Patterns of nicotinic receptor antagonism: nicotine discrimination studies.

Jutkiewicz EM, Brooks EA, Kynaston AD, Rice KC, Woods JH.

J Pharmacol Exp Ther. 2011 Oct;339(1):194-202. doi: 10.1124/jpet.111.182170. Epub 2011 Jul 5.

11.

Effects of varenicline and mecamylamine on the acquisition, expression, and reinstatement of nicotine-conditioned place preference by drug priming in rats.

Biala G, Staniak N, Budzynska B.

Naunyn Schmiedebergs Arch Pharmacol. 2010 Apr;381(4):361-70. doi: 10.1007/s00210-010-0498-5. Epub 2010 Mar 10.

PMID:
20217050
12.

Drug discrimination in methamphetamine-trained rats: effects of cholinergic nicotinic compounds.

Desai RI, Bergman J.

J Pharmacol Exp Ther. 2010 Dec;335(3):807-16. doi: 10.1124/jpet.110.173773. Epub 2010 Sep 16.

13.

Pharmacologic characterization of a nicotine-discriminative stimulus in rhesus monkeys.

Cunningham CS, Javors MA, McMahon LR.

J Pharmacol Exp Ther. 2012 Jun;341(3):840-9. doi: 10.1124/jpet.112.193078. Epub 2012 Mar 21.

14.

Effects of varenicline on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys.

Gould RW, Czoty PW, Nader SH, Nader MA.

J Pharmacol Exp Ther. 2011 Nov;339(2):678-86. doi: 10.1124/jpet.111.185538. Epub 2011 Aug 19.

15.

The effect of varenicline on the development and expression of nicotine-induced behavioral sensitization and cross-sensitization in rats.

Goutier W, Kloeze MB, McCreary AC.

Addict Biol. 2015 Mar;20(2):248-58. doi: 10.1111/adb.12108. Epub 2013 Nov 20.

PMID:
24251901
16.

Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior.

Turner JR, Castellano LM, Blendy JA.

J Pharmacol Exp Ther. 2010 Aug;334(2):665-72. doi: 10.1124/jpet.110.166280. Epub 2010 Apr 30.

17.

A comparison of brain and behavioral effects of varenicline and nicotine in rats.

King J, Huang W, Chen W, Heffernan M, Shields J, Rane P, Bircher R, DiFranza JR.

Behav Brain Res. 2011 Sep 30;223(1):42-7. doi: 10.1016/j.bbr.2011.04.012. Epub 2011 Apr 17.

PMID:
21527291
18.

Divergent functional effects of sazetidine-a and varenicline during nicotine withdrawal.

Turner JR, Wilkinson DS, Poole RL, Gould TJ, Carlson GC, Blendy JA.

Neuropsychopharmacology. 2013 Sep;38(10):2035-47. doi: 10.1038/npp.2013.105. Epub 2013 Apr 29.

19.

Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia.

Roh S, Hoeppner SS, Schoenfeld D, Fullerton CA, Stoeckel LE, Evins AE.

Psychopharmacology (Berl). 2014 Feb;231(4):765-75. doi: 10.1007/s00213-013-3286-3. Epub 2013 Oct 11.

20.

Analgesic and toxic effects of ABT-594 resemble epibatidine and nicotine in rats.

Boyce S, Webb JK, Shepheard SL, Russell MG, Hill RG, Rupniak NM.

Pain. 2000 Apr;85(3):443-50.

PMID:
10781917

Supplemental Content

Support Center